vs
COMPASS MINERALS INTERNATIONAL INC（CMP）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是COMPASS MINERALS INTERNATIONAL INC的1.9倍（$772.1M vs $396.1M），Revvity净利率更高（12.7% vs 4.7%，领先8.0%），COMPASS MINERALS INTERNATIONAL INC同比增速更快（28.9% vs 5.9%），Revvity自由现金流更多（$161.8M vs $-59.8M），过去两年Revvity的营收复合增速更高（9.0% vs 4.3%）
指南针矿产国际是一家美国上市矿产企业，总部位于堪萨斯州欧弗兰帕克，是盐、氯化镁和硫酸钾等产品的领先生产商。公司面向北美和英国客户供应经处理与未经处理的散装道路除冰盐，同时向全球种植者提供植物营养产品，此外也生产民用除冰、水质调节产品及相关商用产品。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
CMP vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.9倍
$396.1M
营收增速更快
CMP
高出23.1%
5.9%
净利率更高
RVTY
高出8.0%
4.7%
自由现金流更多
RVTY
多$221.6M
$-59.8M
两年增速更快
RVTY
近两年复合增速
4.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $396.1M | $772.1M |
| 净利润 | $18.6M | $98.4M |
| 毛利率 | 16.0% | — |
| 营业利润率 | 9.2% | 14.5% |
| 净利率 | 4.7% | 12.7% |
| 营收同比 | 28.9% | 5.9% |
| 净利润同比 | 178.8% | 3.9% |
| 每股收益（稀释后） | $0.43 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CMPRVTY
| Q4 25 | $396.1M | $772.1M | ||
| Q3 25 | $227.5M | $698.9M | ||
| Q2 25 | $214.6M | $720.3M | ||
| Q1 25 | $494.6M | $664.8M | ||
| Q4 24 | $307.2M | $729.4M | ||
| Q3 24 | $208.8M | $684.0M | ||
| Q2 24 | $202.9M | $691.7M | ||
| Q1 24 | $364.0M | $649.9M |
净利润CMPRVTY
| Q4 25 | $18.6M | $98.4M | ||
| Q3 25 | $-7.2M | $46.7M | ||
| Q2 25 | $-17.0M | $53.9M | ||
| Q1 25 | $-32.0M | $42.2M | ||
| Q4 24 | $-23.6M | $94.6M | ||
| Q3 24 | $-48.3M | $94.4M | ||
| Q2 24 | $-43.6M | $55.4M | ||
| Q1 24 | $-38.9M | $26.0M |
毛利率CMPRVTY
| Q4 25 | 16.0% | — | ||
| Q3 25 | 16.9% | 53.6% | ||
| Q2 25 | 19.2% | 54.5% | ||
| Q1 25 | 15.5% | 56.5% | ||
| Q4 24 | 11.2% | — | ||
| Q3 24 | 9.3% | 56.3% | ||
| Q2 24 | 16.1% | 55.7% | ||
| Q1 24 | 19.7% | 54.6% |
营业利润率CMPRVTY
| Q4 25 | 9.2% | 14.5% | ||
| Q3 25 | 5.3% | 11.7% | ||
| Q2 25 | 7.4% | 12.6% | ||
| Q1 25 | -0.6% | 10.9% | ||
| Q4 24 | 0.2% | 16.3% | ||
| Q3 24 | -14.3% | 14.3% | ||
| Q2 24 | 2.9% | 12.4% | ||
| Q1 24 | -10.8% | 6.8% |
净利率CMPRVTY
| Q4 25 | 4.7% | 12.7% | ||
| Q3 25 | -3.2% | 6.7% | ||
| Q2 25 | -7.9% | 7.5% | ||
| Q1 25 | -6.5% | 6.4% | ||
| Q4 24 | -7.7% | 13.0% | ||
| Q3 24 | -23.1% | 13.8% | ||
| Q2 24 | -21.5% | 8.0% | ||
| Q1 24 | -10.7% | 4.0% |
每股收益（稀释后）CMPRVTY
| Q4 25 | $0.43 | $0.86 | ||
| Q3 25 | — | $0.40 | ||
| Q2 25 | $-0.41 | $0.46 | ||
| Q1 25 | $-0.77 | $0.35 | ||
| Q4 24 | $-0.57 | $0.77 | ||
| Q3 24 | $-1.17 | $0.77 | ||
| Q2 24 | $-1.05 | $0.45 | ||
| Q1 24 | $-0.94 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $46.7M | $919.9M |
| 总债务越低越好 | $890.0M | — |
| 股东权益账面价值 | $260.5M | $7.3B |
| 总资产 | $1.5B | $12.2B |
| 负债/权益比越低杠杆越低 | 3.42× | — |
8季度趋势，按日历期对齐
现金及短期投资CMPRVTY
| Q4 25 | $46.7M | $919.9M | ||
| Q3 25 | $59.7M | $931.4M | ||
| Q2 25 | $79.4M | $991.8M | ||
| Q1 25 | $49.5M | $1.1B | ||
| Q4 24 | $45.8M | $1.2B | ||
| Q3 24 | $20.2M | $1.2B | ||
| Q2 24 | $12.8M | $2.0B | ||
| Q1 24 | $38.3M | $1.7B |
总债务CMPRVTY
| Q4 25 | $890.0M | — | ||
| Q3 25 | $839.8M | — | ||
| Q2 25 | $833.4M | — | ||
| Q1 25 | $807.6M | — | ||
| Q4 24 | $974.4M | — | ||
| Q3 24 | $921.2M | — | ||
| Q2 24 | $875.1M | — | ||
| Q1 24 | $877.2M | — |
股东权益CMPRVTY
| Q4 25 | $260.5M | $7.3B | ||
| Q3 25 | $234.1M | $7.4B | ||
| Q2 25 | $249.8M | $7.6B | ||
| Q1 25 | $236.5M | $7.6B | ||
| Q4 24 | $263.0M | $7.7B | ||
| Q3 24 | $316.6M | $7.9B | ||
| Q2 24 | $352.1M | $7.9B | ||
| Q1 24 | $400.4M | $7.8B |
总资产CMPRVTY
| Q4 25 | $1.5B | $12.2B | ||
| Q3 25 | $1.5B | $12.1B | ||
| Q2 25 | $1.5B | $12.4B | ||
| Q1 25 | $1.5B | $12.4B | ||
| Q4 24 | $1.7B | $12.4B | ||
| Q3 24 | $1.6B | $12.8B | ||
| Q2 24 | $1.6B | $13.4B | ||
| Q1 24 | $1.7B | $13.4B |
负债/权益比CMPRVTY
| Q4 25 | 3.42× | — | ||
| Q3 25 | 3.59× | — | ||
| Q2 25 | 3.34× | — | ||
| Q1 25 | 3.41× | — | ||
| Q4 24 | 3.70× | — | ||
| Q3 24 | 2.91× | — | ||
| Q2 24 | 2.49× | — | ||
| Q1 24 | 2.19× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-37.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $-59.8M | $161.8M |
| 自由现金流率自由现金流/营收 | -15.1% | 21.0% |
| 资本支出强度资本支出/营收 | 5.8% | 2.6% |
| 现金转化率经营现金流/净利润 | -1.99× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $94.1M | $509.4M |
8季度趋势，按日历期对齐
经营现金流CMPRVTY
| Q4 25 | $-37.0M | $182.0M | ||
| Q3 25 | $-6.9M | $138.5M | ||
| Q2 25 | $21.8M | $134.3M | ||
| Q1 25 | $186.9M | $128.2M | ||
| Q4 24 | $-4.1M | $174.2M | ||
| Q3 24 | $-12.7M | $147.9M | ||
| Q2 24 | $-6.8M | $158.6M | ||
| Q1 24 | $86.2M | $147.6M |
自由现金流CMPRVTY
| Q4 25 | $-59.8M | $161.8M | ||
| Q3 25 | $-22.8M | $120.0M | ||
| Q2 25 | $3.8M | $115.5M | ||
| Q1 25 | $172.9M | $112.2M | ||
| Q4 24 | $-25.9M | $149.8M | ||
| Q3 24 | $-33.6M | $125.6M | ||
| Q2 24 | $-21.5M | $136.6M | ||
| Q1 24 | $56.2M | $129.7M |
自由现金流率CMPRVTY
| Q4 25 | -15.1% | 21.0% | ||
| Q3 25 | -10.0% | 17.2% | ||
| Q2 25 | 1.8% | 16.0% | ||
| Q1 25 | 35.0% | 16.9% | ||
| Q4 24 | -8.4% | 20.5% | ||
| Q3 24 | -16.1% | 18.4% | ||
| Q2 24 | -10.6% | 19.7% | ||
| Q1 24 | 15.4% | 20.0% |
资本支出强度CMPRVTY
| Q4 25 | 5.8% | 2.6% | ||
| Q3 25 | 7.0% | 2.6% | ||
| Q2 25 | 8.4% | 2.6% | ||
| Q1 25 | 2.8% | 2.4% | ||
| Q4 24 | 7.1% | 3.4% | ||
| Q3 24 | 10.0% | 3.3% | ||
| Q2 24 | 7.2% | 3.2% | ||
| Q1 24 | 8.2% | 2.7% |
现金转化率CMPRVTY
| Q4 25 | -1.99× | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | — | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CMP
| Highway Deicing Salt | $210.8M | 53% |
| Consumer Industrial Salt | $120.7M | 30% |
| Plant Nutrition | $60.8M | 15% |
| Transferred Over Time | $2.8M | 1% |
| Other | $1.0M | 0% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
